Search

Your search keyword '"Feagan, B"' showing total 11 results
Start Over Author "Feagan, B" Publisher bmj
11 results on '"Feagan, B"'

1. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1

Author

Rutgeerts, P, primary, Gasink, C, additional, Blank, M, additional, Lang, Y, additional, Johanns, J, additional, Gao, L-L, additional, Sands, B, additional, Hanauer, S, additional, Feagan, B, additional, Targan, S, additional, Ghosh, S, additional, de Villiers, W, additional, Colombel, J-F, additional, Lee, SD, additional, Desreumaux, P, additional, Loftus, EV, additional, Vermeire, S, additional, and Sandborn, WJ, additional

Published
2016
Full Text
View/download PDF

3. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A’Human MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2: Abstract OC-007 Table 1

Author

Feagan, B, primary, Gasink, C, additional, Lang, Y, additional, Friedman, JR, additional, Johanns, J, additional, Gao, L-L, additional, Sands, B, additional, Hanauer, S, additional, Rutgeerts, P, additional, Targan, S, additional, Ghosh, S, additional, de Villiers, W, additional, Colombel, J-F, additional, Tulassay, Z, additional, Seidler, U, additional, and Sandborn, WJ, additional

Published
2016
Full Text
View/download PDF

9. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Author

Van Assche, G, primary, Sandborn, W J, additional, Feagan, B G, additional, Salzberg, B A, additional, Silvers, D, additional, Monroe, P S, additional, Pandak, W M, additional, Anderson, F H, additional, Valentine, J F, additional, Wild, G E, additional, Geenen, D J, additional, Sprague, R, additional, Targan, S R, additional, Rutgeerts, P, additional, Vexler, V, additional, Young, D, additional, and Shames, R S, additional

Published
2006
Full Text
View/download PDF

11. Development of an index to define overall disease severity in IBD

Author

Richard B. Gearry, Julián Panés, Remo Panaccione, Gerassimos J. Mantzaris, Curt Tysk, Charles N. Bernstein, Stefan Schreiber, Anne M. Griffiths, Edward V. Loftus, Siew C. Ng, Ioannis E. Koutroubakis, Cynthia B. Whitman, Simon Travis, Mark S. Silverberg, Laurent Peyrin-Biroulet, Brian G. Feagan, William J. Sandborn, Gerhard Rogler, Bruce E. Sands, Silvio Danese, Geert R. D'Haens, Balfour R. Sartor, Jean-Frederic Colombel, Stephen B. Hanauer, Corey A. Siegel, Francesco Pallone, Walter Reinisch, Jonas Halfvarson, Dermot P.B. McGovern, Bjørn Moum, Peter L. Lakatos, Colm O'Morain, Brennan Spiegel, Robert H. Riddell, Christoph Gasche, Wolfgang Kruis, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Siegel, Ca, Whitman, Cb, Spiegel, Bmr, Feagan, B, Sands, B, Loftus, Ev, Panaccione, R, D'Haens, G, Bernstein, Cn, Gearry, R, Ng, Sc, Mantzaris, Gj, Sartor, B, Silverberg, M, Riddell, R, Koutroubakis, Ie, O'Morain, C, Lakatos, Pl, Mcgovern, Dpb, Halfvarson, J, Reinisch, W, Rogler, G, Kruis, W, Tysk, C, Schreiber, S, Danese, S, Sandborn, W, Griffiths, A, Moum, B, Gasche, C, Pallone, F, Travis, S, Panes, J, Colombel, Jf, Hanauer, S, and Peyrin-Biroulet, L

Subjects
Adult, Male, medicine.medical_specialty, Abdominal Abscess, Activities of daily living, Delphi Technique, Disease, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Disease severity, Internal medicine, Activities of Daily Living, Intestinal Fistula, Humans, Medicine, In patient, Intestinal Mucosa, Abscess, Aged, Biological Products, Crohn's disease, biology, business.industry, C-reactive protein, Gastroenterology, Middle Aged, medicine.disease, Ulcerative colitis, Surgery, C-Reactive Protein, 030220 oncology & carcinogenesis, biology.protein, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, Symptom Assessment, business
Abstract

Background and aimDisease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC.MethodsUsing a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute.ResultsFor CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities.ConclusionsBased on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results